2023-11-07 07:00:00
A brand of the group
1699363773
#Refocused #fine #chemicals #Pithiviers #Grasse #sites #Axyntis #returns #growth
Tag:
Pharma
“Animal vaccination has a crucial role to play,” recalls Marc Prikazsky, CEO of Ceva Animal Health
written by Alexandra Hartman Editor-in-Chief
2023-10-26 06:00:00
L’USINENOUVELLE.comleader in B2B professional information, offers you the opportunity to follow economic and industrial news from the automotive and new mobility, aeronautics and space, agri-food, energy and sustainable development, health, cosmetics and luxury, chemistry, transport, construction and defense sectors. , plastics processing, metallurgy, raw materials and materials, consumer goods, electronics, IT, telecommunications, cybersecurity, digital and new technologies.
A brand of the group
1698533363
#Animal #vaccination #crucial #role #play #recalls #Marc #Prikazsky #CEO #Ceva #Animal #Health
First patient treated with Henlius’ anti-PD-1 mAb serplulimab in Europe in the MRCT phase 3 study for the first-line treatment of LS-SCLC
written by Alexandra Hartman Editor-in-Chief
2023-10-27 07:12:06
Shanghai (ots/PRNewswire) – Shanghai Henlius Biotech, Inc. (2696.HK) announced that the first patient in Europe in the international multicenter Phase 3 clinical trial (NCT05353257) of the self-developed anti-PD-1 mAb HANSIZHUANG (serplulimab) in combination with Chemotherapy and concurrent radiotherapy were treated in patients with advanced-stage small cell lung cancer (LS-SCLC) in the EU country of Latvia. So far, the first patients have been treated in China, the USA, Australia and other countries and regions.
According to GLOBOCAN 2020, lung cancer (LC) is the second most diagnosed cancer worldwide and the one with the highest mortality. Recently, HANSIZHUANG was recommended for the treatment of ES-SCLC in the 2022 CSCO Guidelines for the Diagnosis and Treatment of Small Cell Lung Cancer. Henlius continues to explore immuno-oncology therapy for LS-SCLC with the goal of providing patients with more effective treatment.
HANSIZHUANG is the first innovative mAb developed by Henlius. It was approved by the NMPA for the treatment of MSI-H solid tumors, non-small cell lung cancer (sqNSCLC) and ES-SCLC, and esophageal squamous cell carcinoma (ESCC) and has since been proven in 40,000 patients in China. In terms of unmet clinical needs, Henlius covers the full spectrum of first-line treatment of LC. Two global, multicenter Phase 3 clinical trials of sqNSCLC and ES-SCLC were conducted in China, Turkey, Poland, Georgia and other countries and regions, with over 30% of the total enrolled subjects being white, providing greater case diversity clinical research offers. ASTRUM-005, the international multicenter phase 3 study in patients with ES-SCLC, was conducted in JAMA, one of the four leading medical journals in the world. This makes ASTRUM-005 the first in JAMA published study on immunotherapy for SCLC. In addition, HANSIZHUANG has received orphan drug designation from the US Food and Drug Administration (FDA) and the European Commission (EC) for the treatment of SCLC. The European Medicines Agency (EMA) has validated the application for HANSIZHUANG in combination with chemotherapy for the first-line treatment of ES-SCLC. It is worth noting that the first patient was treated in a bridging head-to-head study in the US comparing HANSIZHUANG with standard therapy atezolizumab (anti-PD-L1 mAb) for the first-line treatment of ES-SCLC.
Questions & Contact:
Bella Zhou,
+86-13917530919
1698391364
#patient #treated #Henlius #antiPD1 #mAb #serplulimab #Europe #MRCT #phase #study #firstline #treatment #LSSCLC
2023-10-16 15:40:21
Vienna (OTS) – With the new app RandomCoffee Viatris Austria strengthens team spirit and brings together colleagues from different departments, both inside and outside. The app always brings two colleagues together randomly, who then meet virtually or in person for a coffee chat in order to get to know each other and their everyday work better and thus generate mutual understanding.
Focus on employee well-being
More and more companies are recognizing the value of employee well-being – i.e. the focus on the physical, mental and social well-being of their employees. The topic is gaining importance worldwide as it has an increasing impact on the success and performance of companies. Viatris’ mission is to enable people around the world and at every stage of life to live healthier lives. This applies not only to patients, but also to Viatris employees – which is why employee well-being is a top priority in the company.
With RandomCoffee Viatris Austria presents a modern way to bring employees together and promote personal exchange. Two colleagues are randomly brought together and asked via chat to have a coffee chat – either in person or virtually. The aim of this app is to ensure that colleagues have more contact with each other, get to know each other better and find a common goal in (collaborative) work. “Tools like RandomCoffee “We support companies in promoting the well-being of their employees and at the same time increasing their understanding of each other’s work and job satisfaction,” says Claudia Handl, Head of Communication, Public Affairs & Market Access at Viatris Austria.
Committed employer when it comes to team spirit
“The health and well-being of our employees are of great importance to us,” says Julia Reiter, Head of Human Relations at Viatris Austria. “Viatris Austria is a pioneer in strengthening team spirit and increasing the well-being of employees.” After the Austrian team received an award as a Great Place to Work in June, the first Global Wellbeing took place at Viatris last week with “Elevate”. week. In this program, employees had the opportunity to take part in various events on the topics of mental health, work with meaning and personal development. Viatris Austria regularly organizes meaningful team building activities for its employees: as part of Caritas Austria’s Social Team Day, different teams from Viatris Austria cook lunch for homeless and socially disadvantaged people. This not only promotes cohesion within the team, but also gives something back to society, because: “Cooking and serving over 100 portions together in a few hours is a challenge for the whole team,” says Dietrich Göller, Managing Director of Viatris Austria
About Viatris
Viatris Inc. (NASDAQ: VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and branded products, combining the best of both to more holistically address healthcare needs worldwide. Our mission is to help people around the world live healthier lives at every stage of life and provide comprehensive access to medicines. In 2022 alone, we provided around 1 billion patients around the world with high-quality medicines. With our exceptionally extensive and diverse portfolio of medicines, a unique global supply chain designed to reach more people when and where they need it, and the scientific expertise to address some of the world’s greatest health challenges, access at Viatris a great importance. We are able to capture all moments of life, from birth to end of life, from acute to chronic illnesses. We are headquartered in the USA, with global centers in Pittsburgh, Shanghai and Hyderabad, India. Find out more on viatris.com and investor.viatris.comfollow us too Twitter, LinkedIn Instagram and YouTube.
In Austria, the Viatris Group includes Mylan Österreich GmbH (including former Upjohn products) and Arcana Arzneimittel GmbH. The portfolio in Austria includes more than 500 products, including originals and (branded) generics. Both prescription and over-the-counter preparations cover a wide range of therapeutic areas. Further information can also be found at www.viatris.at.
Questions & Contact:
Viatris Austria
Claudia Handl
Head Communications, Public Affairs & Market Access
+43 664 6253110; Claudia.Handl@viatris.com
Agency/journalist service
Michael Leitner/Public Health PR
+43 1 6020530 92, Michael.leitner@publichealth.at
1697470887
#Viatris #Austria #promotes #coffee #chats #among #colleagues